# Combination Therapy for the Treatment of Diffuse Midline Gliomas

Source: https://onco.cc/trials/nct05009992/  
OnCo record `nct05009992` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of DNX-2401 run by University of California, San Francisco, now recruiting.

## Summary

Combination Therapy for the Treatment of Diffuse Midline Gliomas is a phase 2 interventional study registered as NCT05009992 by University of California, San Francisco, with 360 participants planned, started 2021-10-20. Conditions recorded: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma and WHO Grade III Glioma. Interventions recorded: ONC201, Radiation Therapy, Paxalisib and DNX-2401.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05009992
- Phase: 2
- Setting: A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
- Sponsor: University of California, San Francisco
- Enrolled: 360

## Sources

- ClinicalTrials.gov NCT05009992: https://clinicaltrials.gov/study/NCT05009992

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Diffuse midline glioma, H3 K27-altered (including DIPG)](https://onco.cc/cancers/dipg-dmg/)
- drugs: [DNX-2401](https://onco.cc/drugs/dnx-2401/)
- companies: [DNAtrix](https://onco.cc/companies/dnatrix/)

---
JSON: https://onco.cc/api/v1/entities/nct05009992.json